Eupraxia Pharmaceuticals Inc.
EPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001581178
No open-market purchases or sales by Eupraxia Pharmaceuticals Inc. insiders were filed in the last 90 days; 67 institutions reported holding it in 13F filings for Q2 2026, worth $163.6M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Eupraxia Pharmaceuticals Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +13 vs. Q2 2025
- Shares held
- 12.8M
- +10.8M (+550.4%) vs. Q2 2025
- Total value
- $75.3M
- +$64.4M (+591.4%) vs. Q2 2025
- New holders
- 15
- 7 more added
- Sold out
- 2
- 2 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EPRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 67 | $163.6M |
| Q1 2026 | 55 | $160.3M |
| Q4 2025 | 36 | $105.1M |
| Q3 2025 | 27 | $75.3M |
| Q2 2025 | 14 | $10.9M |
| Q1 2025 | 11 | $7.09M |
| Q4 2024 | 9 | $5.63M |
| Q3 2024 | 8 | $4.55M |
| Q2 2024 | 8 | $4.43M |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Eupraxia Pharmaceuticals Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 9 | $53 | 0.00% | +9 | New |
| National Bank of Canada | 882 | $5.03K | 0.00% | +152+20.8% | Added |
| Federation des caisses Desjardins du Quebec | 9,091 | $51.6K | 0.00% | +9,091 | New |
| TD Waterhouse Canada Inc. | 9,600 | $56.2K | 0.00% | 00.0% | Unchanged |
| TCI Wealth Advisors, Inc. | 11,000 | $64.9K | 0.00% | +11,000 | New |
| Integrated Wealth Concepts LLC | 12,000 | $70.8K | 0.00% | +12,000 | New |
| CIBC World Markets Inc. | 15,000 | $88.4K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 16,467 | $97.2K | 0.00% | −2,250−12.0% | Reduced |
| Acadian Asset Management LLC | 21,400 | $125.0K | 0.00% | +21,400 | New |
| Guardian Partners Inc. | 24,130 | $147.4K | 0.01% | +24,130 | New |
| Raymond James Financial Inc | 33,373 | $196.9K | 0.00% | +21,161+173.3% | Added |
| Bank of Montreal | 37,250 | $219.4K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 40,100 | $236.6K | 0.00% | +300+0.8% | Added |
| Bank of America Corp | 45,577 | $268.9K | 0.00% | +33,018+262.9% | Added |
| Ingalls & Snyder LLC | 59,100 | $349.0K | 0.01% | +21,900+58.9% | Added |
| UBS Group AG | 95,756 | $565.0K | 0.00% | +58,257+155.4% | Added |
| Alyeska Investment Group, L.P. | 250,000 | $1.48M | 0.00% | +250,000 | New |
| Affinity Asset Advisors, LLC | 300,000 | $1.77M | 0.16% | +300,000 | New |
| Velan Capital Investment Management LP | 352,000 | $2.08M | 1.95% | +352,000 | New |
| Royal Bank of Canada | 428,804 | $2.53M | 0.00% | +220+0.1% | Added |
| Logos Global Management LP | 900,000 | $5.31M | 0.52% | +900,000 | New |
| Ally Bridge Group (NY) LLC | 915,000 | $5.40M | 4.52% | +915,000 | New |
| Great Point Partners LLC | 1,200,000 | $7.08M | 2.96% | +1,200,000 | New |
| Scotia Capital Inc. | 1,277,885 | $7.25M | 0.03% | −14,104−1.1% | Reduced |
| Balyasny Asset Management LLC | 1,350,000 | $7.96M | 0.02% | +1,350,000 | New |
| Vivo Capital, LLC | 1,350,000 | $7.96M | 0.64% | +1,350,000 | New |
| Beutel, Goodman & Co Ltd. | 4,058,899 | $23.9M | 0.14% | +4,058,899 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −18,236−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −10,700−100.0% | Sold out |